MétaCan
Menu
Back to cohort
Record W1997237519 · doi:10.1111/jdv.12909

Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review

2014· review· en· W1997237519 on OpenAlexaff
Patrick Fleming, C. Roubille, Vincent Richer, Tara Starnino, Collette McCourt, Alexandra McFarlane, S. Siu, J. Kraft, Charles Lynde, Janet Pope, Stephanie Keeling, Jan Dutz, Louis Bessette, Robert Bissonnette, Boulos Haraoui, Wayne Gulliver

Bibliographic record

VenueJournal of the European Academy of Dermatology and Venereology · 2014
Typereview
Languageen
FieldImmunology and Microbiology
TopicPsoriasis: Treatment and Pathogenesis
Canadian institutionsMemorial University of NewfoundlandCentre Hospitalier de l’Université de MontréalInnovaderm (Canada)Centre hospitalier universitaire de QuébecUniversity of British ColumbiaUniversity of TorontoWestern UniversityHôpital du Sacré-Cœur de MontréalLynde Centre for DermatologyUniversity of AlbertaUniversité de MontréalHôpital Saint-Luc
FundersSanofi
KeywordsMedicineAdalimumabUstekinumabEtanerceptPsoriasisPlaceboRandomized controlled trialDepression (economics)Internal medicineBeck Depression InventoryPhysical therapyClinical trialDermatologyAnxietyPsychiatryTumor necrosis factor alphaAlternative medicine

Abstract

fetched live from OpenAlex

BACKGROUND: Twenty to fifty percent of patients with psoriasis have depressive symptoms. OBJECTIVE: To describe the effects of biologics (tumour necrosis factor inhibitors [TNFi] or interleukin 12/23 inhibitors [IL-12/23i]) on depressive symptoms in patients with psoriasis. METHODS: Electronic databases were searched for randomized controlled trials (RCTs) examining the effects of biologics on depressive symptoms in adults with psoriasis. RESULTS: Of the 305 publications identified, three RCTs were included in a systematic review. In a trial evaluating ustekinumab, mean change in Hospital and Anxiety Depression Rating Scale at 24 weeks from baseline was 3.1 with ustekinumab (P < 0.001) vs. 0.21 with placebo (not significant). In a trial evaluating adalimumab, mean change in Zung Self-Rating Depression Scale at 12 weeks from baseline was -6.7 with adalimumab vs. -1.5 with placebo. In a trial evaluating etanercept, the between-group difference at 12 weeks in Beck Depression Inventory Scale was 1.8 (95% CI: 0.6, 2.90) in favour of etanercept over placebo. Limitations are that diagnostic criteria for depression were not used and scales and data from individual RCTs could not be combined. CONCLUSION: Adalimumab, etanercept and ustekinumab were associated with statistically significant reductions in depressive symptom scores using various scales in patients with moderate-to-severe psoriasis.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Systematic review · Consensus signal: Systematic review
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.147
Threshold uncertainty score0.940

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0050.001
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0010.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.012
GPT teacher head0.265
Teacher spread0.253 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designSystematic review
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations104
Published2014
Admission routes1
Has abstractyes

Explore more

Same venueJournal of the European Academy of Dermatology and VenereologySame topicPsoriasis: Treatment and PathogenesisFrench-language works237,207